SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending amid a mixed sentiment, with some traders pointing to a recent report highlighting security flaws in its battlefield communication system while others dismiss it as a hit piece designed to create a buying opportunity. The community is actively debating the company's valuation and future growth prospects in the AI space, with some calling it overvalued and others believing it has significant long-term potential. Despite the debate, some are taking advantage of the dip and loading up on shares, anticipating a rebound.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid excitement over the company's shift to quantum computing for cryptocurrency applications, particularly its partnership related to LightSolver's laser-based processing units. The community is actively discussing the potential for energy savings and comparing it to other trending quantum stocks. Some traders are closely watching its threshold list status and awaiting news of potential contracts.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its potential as a culture coin and a symbol of freedom within the digital currency space. The project is drawing attention for its association with the cannabis culture and its aim to provide a decentralized financial tool. Community is also celebrating the 420k BURN event with a livestream, calling it a significant step for the project.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending due to Citron Research's positive outlook, sparking significant trading volume and community discussion about a potential short squeeze. Community members are debating the company's long-term prospects, comparing it to other telehealth plays, and speculating on factors such as potential acquisitions and partnerships. Overall, the conversation centers on whether Teladoc is undervalued and poised for a breakout.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

Astrotech Corp. engages in the mass spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly-owned subsidiaries. Its business units include 1st Detect, BreathTech, and AgLab. The company was founded in 1984 and is headquartered in Austin, TX.

Astrotech Corp

ASTC is experiencing increased volume and momentum, leading to community speculation about a potential breakout and larger move. Some traders are attributing the increased interest to the company's expansion of operations. Others suggest possible confusion with AST SpaceMobile (ASTS) as a catalyst for the current trading activity.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as traders discuss its potential for continuation and speculate on government support following news of White House talks. Some community members are drawing parallels to previous rare earth stock surges, while others point to the company's expansion into AI data center power and modular revenue growth as catalysts. Discussions also mention short interest and potential for a squeeze.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending as investors discuss its potential role in solving AI's energy consumption challenges, with some viewing it as a more energy-efficient alternative to classical computers. The community is actively debating the company's valuation and long-term prospects in the burgeoning quantum computing sector, especially when compared to its peers. Positive analyst coverage and potential big tech partnerships are also fueling the bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

Futures Fall As Jittery Traders Take Cover Ahead Of Payrolls

Futures Fall As Jittery Traders Take Cover Ahead Of Payrolls

 US equity futures are lower as traders took a cautious stance ahead of US jobs data that will offer fresh insight on the...

Artificial intelligence data cloud company Snowflake, Inc. (<a class="mention" data-mention="$SNOW" data-symbol-id="SNOW" href="https://stocktwits.com/symbol/SNOW" target="_blank">$SNOW</a>) reported Wednesday after the market close fiscal year third-quarter results that exceeded estimates and upped its product revenue guidance for the year. The company also announced a deal to buy Datavolo.Bozeman, Montana-based Snowflake reported third-quarter non-GAAP earnings per share (EPS) of $0.20, down from $0.25 earned a year-ago. The bottom-line result exceeded the consensus estimate of $0.15 per share.Quarterly revenue climbed 28% year-on-year (YoY) from $734.17 million to $942.09 million, surpassing the $899.31-million consensus estimate. Product revenue accounted for over 95% of the total and improved 29%.Among the key operating metrics, the number of customers with trailing 12-month product revenue greater than $1 million, was 542 at the end of the third quarter, up 55% YoY. Forbes Global 500 customers climbed 8% to 754.Net revenue retention rate was 127% as of Oct. 31.Sridhar Ramaswamy, CEO of Snowflake said, "Snowflake delivered a strong third quarter, with product revenue of $900 million, up 29% year-over-year, and remaining performance obligations of $5.7 billion, with year-over-year growth accelerating to 55%."Remaining performance obligations refers to the amount of contracted future revenue that hasn’t been recognized yet."Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform. That is what’s leading us to win new logo after new logo, expand within our customer base, and displace our competition over and over again."For the fourth quarter, the company expects product revenue of $906 million to $911 million, representing 23% YoY growth, and operating income margin of 4%.The company upped its full-year 2025 product revenue guidance from $3.36 billion to $3.43 billion.Separately, the company announced a definitive agreement to acquire open data integration platform Datavolo. "Together, Datavolo and Snowflake will both simplify data engineering workloads and deliver unmatched data interoperability and extensibility – a building block for effective enterprise AI," Snowflake said.<figure class="image"><a href="https://stocktwits.com/symbol/SNOW"><img style="aspect-ratio:623/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/snow_sentiment_6c6bf75593.png" alt="snow-sentiment.png" width="623" height="135"></a><figcaption>SNOW sentiment and message volume November 21, 2024, premarket as of 6:27 &nbsp;am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward Snowflake stock improved from ‘bullish’ a day ago (58/100) to ‘extremely bullish’ (95/100), with message volume staying ‘extremely high.’ The stock was among the top 10 trending stocks on the platform.Following the results, analysts at JPMorgan, Barclays and Jefferies raised their price targets for the stock,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=SNOW">according</a> to the Fly. Analysts at Jeffries welcomed the beat-and-raise quarter and said the company has a “massive runway” even as iceberg headwinds were “better than feared.”Stocktwits platform users were bracing for a “parabolic” day, with the analysts’ reratings.<stembedurl>https://stocktwits.com/WSBisforstupidppl/message/593469035</stembedurl>In premarket trading on Thursday, as of 6:27 am ET, Snowflake shares were up 21.74% at $157.20, marking the highest level since late-May. The stock has underperformed the broader market this year, having lost over 35%.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-results-exceed-expectations/cJ46vCoRXL">Nvidia Stock Falls Despite Q3 Beat, Positive Commentary On Blackwell Demand: Retail Stays Upbeat</a>

 Number of Snowflake customers with trailing 12-month product revenue greater than $1 million jumped 55% YoY.

Snowflake Stock Jumps Over 21% In Premarket Following Beat-and-Raise Q3: Retail Braces For ‘Parabolic’ Run

Snowflake CEO Sridhar Ramaswamy said, “Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform.”

Equity

Snowflake CEO Sridhar Ramaswamy said, “Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform.”


IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb executive as CEO. The company aims to extend its cash runway into 2027.
read...

The Analyst Verdict: IGM Biosciences In The Eyes Of 5 Experts

Latest Ratings for IGMS
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyDowngradesOverweightEqual-Weight Dec 2021StifelMaintainsBuy
 View More Analyst Ratings...

IGM Biosciences Refocuses Genzyme Collaboration on Immunology

IGM Biosciences (IGMS) has shared an update. IGM Biosciences, Inc. has shifted its collaboration with Genzyme Corporation to focus solely on immuno...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

IGM Biosciences Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

IGMS
IGM Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IGMS News

IGMS IGM Biosciences Inc